Let’s be clear.
The article you linked starts with a disclosure line that says “none.” But scroll to the end and you’ll find the truth:
“D.M. is an inventor on patents related to gene and cell therapy, filed by the University of Pennsylvania and the University of Geneva, and is a consultant for Limula Therapeutics and MPC Therapeutics.”
That’s a conflict of interest. And not a minor one.
Limula Therapeutics is building closed-system, GMP-ready automated manufacturing platforms for cell therapies. That puts them in direct conceptual competition with Flaskworks’ Eden system, the same Eden that Northwest Biotherapeutics already owns, has integrated, and is preparing for deployment under the UK’s SI 87 regulatory framework.
MPC Therapeutics is even further removed, but the overlap is strategic. They’re attempting to develop T-cell–based metabolic immunotherapies: early stage, preclinical, and with no published efficacy in glioblastoma, dendritic cell systems, or intratumoral delivery. Still, their ambitions land in the same immunological territory NWBO already occupies and has validated. Their best chance isn’t to compete with DCVax. It’s to undermine it and reposition their own platform before DCVax sets the bar.
So when someone aligned with both of those companies publishes a paper criticizing the DCVax-L trial, that isn’t independent analysis. That’s strategic positioning.
And notice what the paper didn’t challenge.
It didn’t deny that DCVax-L extended survival.
It didn’t refute the biology.
It didn’t question the GMP reproducibility of Eden or Flaskworks.
What it attacked
Bullish
Market Data 
Markets 
